Avidity Biosciences, Inc. Financials
This page shows Avidity Biosciences, Inc. (RNA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Avidity Biosciences, Inc. has an operating margin of -3477.4%, meaning the company retains $-3477 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -2464.4% the prior year.
Avidity Biosciences, Inc.'s revenue grew 14.0% year-over-year to $10.9M, a solid pace of expansion. This earns a growth score of 69/100.
Avidity Biosciences, Inc. carries a low D/E ratio of 0.10, meaning only $0.10 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 15.73, Avidity Biosciences, Inc. holds $15.73 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Avidity Biosciences, Inc. generated -$300.9M in operating cash flow, capex of $7.1M consumed most of it, leaving -$307.9M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Avidity Biosciences, Inc. passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Avidity Biosciences, Inc. generates $0.93 in operating cash flow (-$300.9M OCF vs -$322.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Avidity Biosciences, Inc. generated $10.9M in revenue in fiscal year 2024. This represents an increase of 14.0% from the prior year.
Avidity Biosciences, Inc.'s EBITDA was -$376.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 61.1% from the prior year.
Avidity Biosciences, Inc. generated -$307.9M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 149.8% from the prior year.
Avidity Biosciences, Inc. reported -$322.3M in net income in fiscal year 2024. This represents a decrease of 51.9% from the prior year.
Avidity Biosciences, Inc. earned $-2.89 per diluted share (EPS) in fiscal year 2024. This represents an increase of 0.7% from the prior year.
Avidity Biosciences, Inc. held $219.9M in cash against $0 in long-term debt as of fiscal year 2024.
Avidity Biosciences, Inc. had 120M shares outstanding in fiscal year 2024. This represents an increase of 51.6% from the prior year.
Avidity Biosciences, Inc.'s operating margin was -3477.4% in fiscal year 2024, reflecting core business profitability. This is down 1013.0 percentage points from the prior year.
Avidity Biosciences, Inc.'s net profit margin was -2957.7% in fiscal year 2024, showing the share of revenue converted to profit. This is down 737.8 percentage points from the prior year.
Avidity Biosciences, Inc. invested $303.6M in research and development in fiscal year 2024. This represents an increase of 59.0% from the prior year.
Avidity Biosciences, Inc. invested $7.1M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 67.1% from the prior year.
RNA Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.5M+224.3% | $3.8M+144.6% | $1.6M-47.1% | $3.0M+45.4% | $2.0M-42.3% | $3.5M+61.6% | $2.2M-22.2% | $2.8M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $154.9M+12.2% | $138.1M+38.8% | $99.5M+4.0% | $95.6M+49.6% | $63.9M-4.3% | $66.8M+26.5% | $52.8M+10.7% | $47.7M |
| SG&A Expenses | $46.3M+25.7% | $36.9M+9.7% | $33.6M+18.6% | $28.3M+36.7% | $20.7M+49.2% | $13.9M-13.8% | $16.1M+17.4% | $13.7M |
| Operating Income | -$188.8M-10.3% | -$171.1M-30.1% | -$131.5M-8.7% | -$121.0M-46.4% | -$82.6M-7.0% | -$77.2M-15.6% | -$66.7M-13.8% | -$58.6M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$174.4M-10.9% | -$157.3M-35.9% | -$115.8M-13.2% | -$102.3M-44.4% | -$70.8M-2.8% | -$68.9M-13.9% | -$60.4M-15.4% | -$52.4M |
| EPS (Diluted) | $-1.27-5.0% | $-1.21-34.4% | $-0.90-12.5% | $-0.80-23.1% | $-0.65+17.7% | $-0.79+1.3% | $-0.80-12.7% | $-0.71 |
RNA Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.1B+55.9% | $1.4B-6.2% | $1.5B-6.7% | $1.6B+16.1% | $1.3B+41.6% | $951.5M+51.4% | $628.6M+9.7% | $573.2M |
| Current Assets | $2.0B+57.2% | $1.3B-12.9% | $1.4B-7.0% | $1.5B+16.1% | $1.3B+42.2% | $934.5M+52.9% | $611.3M+10.0% | $555.5M |
| Cash & Equivalents | $350.2M+43.6% | $243.9M-4.1% | $254.2M+15.6% | $219.9M-61.8% | $575.8M+22.1% | $471.4M+154.7% | $185.1M+116.1% | $85.7M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | $0 | $0-100.0% | $1.6M+42.5% | $1.1M | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $247.9M+40.7% | $176.3M+35.2% | $130.4M-6.2% | $138.9M+9.9% | $126.4M+4.8% | $120.6M-5.6% | $127.8M+129.4% | $55.7M |
| Current Liabilities | $169.9M+25.8% | $135.1M+59.1% | $84.9M-13.4% | $98.0M+16.4% | $84.2M+12.4% | $75.0M-7.1% | $80.7M+65.6% | $48.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.9B+58.2% | $1.2B-10.2% | $1.3B-6.8% | $1.4B+16.7% | $1.2B+47.0% | $830.9M+65.9% | $500.8M-3.2% | $517.5M |
| Retained Earnings | -$1.3B-15.0% | -$1.2B-15.6% | -$1.0B-13.0% | -$893.1M-25.7% | -$710.4M-11.1% | -$639.6M-12.1% | -$570.8M-11.8% | -$510.3M |
RNA Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$156.2M+21.8% | -$199.7M-60.0% | -$124.8M-25.0% | -$99.9M-53.6% | -$65.0M+7.6% | -$70.4M-526.5% | $16.5M+144.9% | -$36.8M |
| Capital Expenditures | $712K-78.7% | $3.3M-10.9% | $3.8M-4.2% | $3.9M+637.5% | $531K-42.0% | $915K+6.0% | $863K-6.5% | $923K |
| Free Cash Flow | -$156.9M+22.7% | -$203.0M-57.9% | -$128.6M-23.9% | -$103.8M-58.4% | -$65.5M+8.1% | -$71.3M-555.9% | $15.6M+141.5% | -$37.7M |
| Investing Cash Flow | -$587.9M-417.0% | $185.5M+18.0% | $157.2M+344.9% | -$64.2M+76.7% | -$274.9M-739.4% | -$32.7M-164.2% | $51.0M+262.1% | -$31.5M |
| Financing Cash Flow | $850.4M+22438.2% | $3.8M+94.8% | $1.9M-85.9% | $13.7M-96.9% | $446.7M+14.7% | $389.4M+1121.2% | $31.9M+79627.5% | $40K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
RNA Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -1513.5%+2935.2pp | -4448.7%+3912.2pp | -8360.9%-4291.3pp | -4069.6%-29.2pp | -4040.4%-1861.8pp | -2178.6%+864.9pp | -3043.5%-963.1pp | -2080.4% |
| Net Margin | -1398.3%+2691.0pp | -4089.3%+3270.7pp | -7360.0%-3920.5pp | -3439.5%+22.3pp | -3461.8%-1518.4pp | -1943.4%+812.8pp | -2756.2%-898.2pp | -1858.0% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -8.2%+3.3pp | -11.5%-3.6pp | -7.9%-1.4pp | -6.5%-1.3pp | -5.3%+2.0pp | -7.2%+2.4pp | -9.6%-0.5pp | -9.1% |
| Current Ratio | 11.57+2.3 | 9.26-7.6 | 16.91+1.2 | 15.73-0.0 | 15.78+3.3 | 12.47+4.9 | 7.58-3.8 | 11.40 |
| Debt-to-Equity | 0.13-0.0 | 0.15+0.0 | 0.100.0 | 0.100.0 | 0.10-0.0 | 0.15-0.1 | 0.26+0.1 | 0.11 |
| FCF Margin | -1257.6%+4019.5pp | -5277.1%+2897.3pp | -8174.3%-4683.3pp | -3491.0%-286.3pp | -3204.7%-1192.4pp | -2012.3%-2725.4pp | 713.1%+2051.4pp | -1338.3% |
Similar Companies
Frequently Asked Questions
What is Avidity Biosciences, Inc.'s annual revenue?
Avidity Biosciences, Inc. (RNA) reported $10.9M in total revenue for fiscal year 2024. This represents a 14.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Avidity Biosciences, Inc.'s revenue growing?
Avidity Biosciences, Inc. (RNA) revenue grew by 14% year-over-year, from $9.6M to $10.9M in fiscal year 2024.
Is Avidity Biosciences, Inc. profitable?
No, Avidity Biosciences, Inc. (RNA) reported a net income of -$322.3M in fiscal year 2024, with a net profit margin of -2957.7%.
What is Avidity Biosciences, Inc.'s earnings per share (EPS)?
Avidity Biosciences, Inc. (RNA) reported diluted earnings per share of $-2.89 for fiscal year 2024. This represents a 0.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Avidity Biosciences, Inc.'s EBITDA?
Avidity Biosciences, Inc. (RNA) had EBITDA of -$376.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Avidity Biosciences, Inc.'s operating margin?
Avidity Biosciences, Inc. (RNA) had an operating margin of -3477.4% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Avidity Biosciences, Inc.'s net profit margin?
Avidity Biosciences, Inc. (RNA) had a net profit margin of -2957.7% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Avidity Biosciences, Inc.'s free cash flow?
Avidity Biosciences, Inc. (RNA) generated -$307.9M in free cash flow during fiscal year 2024. This represents a -149.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Avidity Biosciences, Inc.'s operating cash flow?
Avidity Biosciences, Inc. (RNA) generated -$300.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Avidity Biosciences, Inc.'s total assets?
Avidity Biosciences, Inc. (RNA) had $1.6B in total assets as of fiscal year 2024, including both current and long-term assets.
What are Avidity Biosciences, Inc.'s capital expenditures?
Avidity Biosciences, Inc. (RNA) invested $7.1M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Avidity Biosciences, Inc. spend on research and development?
Avidity Biosciences, Inc. (RNA) invested $303.6M in research and development during fiscal year 2024.
How many shares does Avidity Biosciences, Inc. have outstanding?
Avidity Biosciences, Inc. (RNA) had 120M shares outstanding as of fiscal year 2024.
What is Avidity Biosciences, Inc.'s current ratio?
Avidity Biosciences, Inc. (RNA) had a current ratio of 15.73 as of fiscal year 2024, which is generally considered healthy.
What is Avidity Biosciences, Inc.'s debt-to-equity ratio?
Avidity Biosciences, Inc. (RNA) had a debt-to-equity ratio of 0.10 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Avidity Biosciences, Inc.'s return on assets (ROA)?
Avidity Biosciences, Inc. (RNA) had a return on assets of -20.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Avidity Biosciences, Inc.'s cash runway?
Based on fiscal year 2024 data, Avidity Biosciences, Inc. (RNA) had $219.9M in cash against an annual operating cash burn of $300.9M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Avidity Biosciences, Inc.'s Piotroski F-Score?
Avidity Biosciences, Inc. (RNA) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Avidity Biosciences, Inc.'s earnings high quality?
Avidity Biosciences, Inc. (RNA) has an earnings quality ratio of 0.93x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Avidity Biosciences, Inc.?
Avidity Biosciences, Inc. (RNA) scores 54 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.